MassBioDrive is a next-generation accelerator designed to advance breakthrough science while providing opportunities to innovators from all parts of the life science ecosystem.
Twice a year, we support a small group of groundbreaking scientists by connecting them with business fundamental curriculum, mentorship, industry connections, and equity free prizes – without taking anything in return. Learn more about past Drive cohorts.
Our goal is to help you take that first (big) step outside of the lab by arming you with the business insights and network so your startup can grow more effectively and efficiently.
Announcing the Fall 2022 Cohort
MassBio is proud to announce its Fall 2022 (F22) cohort of groundbreaking scientists and founders.
Based in Omaha, NE
AdductNE is a radiopharmaceutical company spun-out from the University of Nebraska Medical Center (UNMC) in 2019. AdductNE is dedicated to developing targeted imaging and therapeutic agents for cancer.
Based in Mississauga, Ontario, CA
HDAX Therapeutics is developing a targeted therapeutics platform for the safe and efficacious treatment of HDAC-driven pathologies such as neuropathies and cancers by rationally designing therapies to overcome common drug challenges including weak binding, off-target toxicities, and poor pharmacokinetic profiles.
Based in New Haven, CT
Hybridex Biosciences is an early-stage biotech company aiming to enable the next-generation of safe gene editing. Using its tunable antisense nucleic acid platform, developed in labs at Yale University, Hybridex aims to improve the safety and control of CRISPR-based systems to realize the full potential of gene editing therapeutics.
Based in Montreal, Quebec CA
Jenthera Therapeutics is a preclinical biotechnology company leveraging a novel non-viral, non-lipid CRISPR platform for the development of groundbreaking therapeutics. The platform presents tissue-specific delivery, built-in safety, and advanced gene correction capabilities, proposing to unlock new realms of therapeutic possibilities and allow for the development of complex multi-loci corrective gene therapies.
Based in Knoxville, TN
Orion Therapeutics has developed a patented lipid-based nanoparticle capable of safe, effective, and targeted delivery of RNA medicine to diseased tissues to address the delivery barrier to successful gene therapy. This technology will be licensed to pharmaceutical partners to facilitate success of RNA therapeutics and vaccine programs.
Based in Natick, MA
PacDNA is an oligonucleotide therapeutics company that will expand the horizon of this drug modality to include previously inaccessible organs and tissues. Its proprietary oligonucleotide enhancer technology will be a new drug production engine, producing more potent clinical leads with fewer side effects at a lower cost.
Meet our MassBioDrive 2022 Partners
2022 Review Board
James (Jay) Bradner, M.D.
President, Novartis Institutes for BioMedical Research (NIBR)
Christine Brennan, Ph.D.
Managing Director, Vertex Ventures HC
President, Cerevel Therapeutics
Omar H. Khalil
Partner, Santé Ventures
Jen Nwankwo, Ph.D.
Founder and CEO, 1910 Genetics
Chandra Ramanathan, Ph.D.
Global Head of Innovation Hubs, Danaher
2022 Curriculum Experts
Business Plan and Commercialization Strategy
From seed stage businesses to public companies —as you make history, J.P. Morgan will be with you every step of the way. Our bankers and specialists focus on solutions for life sciences companies at all stages—from startups to established businesses, pre-clinical through commercialization. We have decades of experience in the sector and understand the complex financial and regulatory challenges you face. We bring a wealth of expertise and insights to the venture capital space, and we’re ready to help you stay positioned for innovation and growth. We know no two life sciences companies are the same. That’s why our team goes below the surface to support the unique needs of industry subsectors, including biotechnology, biopharmaceuticals, pharmaceuticals, medical devices, medical tools and diagnostics, and CROs, CDMOs and CMOs. Our clients also gain access to vital industry insights from the annual J.P. Morgan Health Conference, along with the rich analysis and research of J.P. Morgan Markets.
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 100,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
IP and Legal
Wilson Sonsini’s Boston office is home to one of the leading life sciences law practices in both the city and New England. The firm focuses on providing practical, business-savvy advice to entrepreneurs and investors as they build tomorrow’s companies. Wilson Sonsini’s Boston office keeps the team in close proximity to the many extraordinary growth enterprises and innovative scientists, engineers, entrepreneurs, and universities in and around the area. The firm’s team frequently represents companies that are significant influencers in the life sciences, technology, energy, and financial industries, among other sectors. The firm’s clients range from early-stage start-ups to public companies, as well as their board and management teams, and also represents leading venture capital and private equity firms, along with other investor institutions.
New regulatory requirements, a flurry of M&A activity, fierce competition, declining margins and rapidly emerging technologies create new complexities for medical device, biotechnology, and pharmaceutical companies. Further, there is growing scrutiny on drug prices along with lengthy and costly R&D cycles. Many life sciences companies are taking new approaches to achieve growth and improve performance, all while focusing on managing risk and maintaining compliance. At KPMG, we have a long track record of helping life sciences organizations define and implement practical solutions to their most complex challenges.
Based in Boston, MA, Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with funding options as well as the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with founding scientists and entrepreneurs to support their vision while allowing a more efficient development model that benefits company founders and early equity holders.
People Strategy and Operations
Marsh McLennan Agency (MMA) provides business insurance, employee health & benefits, retirement, and private client insurance solutions to organizations and individuals seeking limitless possibilities. With over 8,000 colleagues and 160 offices across the United States and Canada, MMA combines the personalized service model of a local consultant with the global resources and expertise of the world’s leading professional services firm, Marsh McLennan (NYSE: MMC). MMA generates more than $2 billion in annualized revenue, making it one of the largest brokerage operations in North America.
2022 Premier Sponsors
During each hybrid eight-week program, we connect you with:
- Six industry-specific curriculum modules led by experts
- A small, dedicated group of industry mentors tailored to fit your needs
- Networking opportunities and industry connections:
- End-of-program Demo Day, where you’ll present your company to the life sciences ecosystem
- 1:1 meeting(s) with life sciences leaders at MassBio’s bi-annual Partnering Weeks
- An equity-free stipend from Bristol Myers Squibb
- Access to and/or resources from MassBioDrive partners including Evaluate, Johnson & Johnson Innovation, Watershed Informatics, Springer Nature, and MassChallenge
MassBioDrive does not take any equity from the companies we support and our program is free to all participants.
The MassBioDrive S23 cohort application will open in early 2023. Please check back for more information.
You’re eligible to apply for MassBioDrive if:
- You have a therapeutic, biologic, or platform technology that you believe can become the next big biotech startup
- Your startup has access to the intellectual property for your science or technology, either through a license agreement or through an option agreement to negotiate a license agreement
- Your startup has raised less than $1 million in equity-based funding
- You will be able to participate in all cornerstone components of the program (curriculum, weekly mentoring sessions, and networking events)
Please note that this is a non-confidential program. Accordingly, do not include any confidential information or any information that could be harmful to your startup should it be disclosed in your application. To learn more about MassBioDrive’s approach to confidentiality, please review our Participant Agreement.
Underscoring MassBio’s commitment to building a diverse, equitable, and inclusive life sciences ecosystem, MassBioDrive is committed to supporting and advancing innovators from traditionally underrepresented backgrounds. Learn more about MassBioDrive’s Code of Conduct here.
Interested in supporting Drive startups? Learn more ways to get involved.